Everything below concerns Lactam bridge. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Increasingly, Zolpidem is being used off-label for the treatment of comatose or vegetative states for brain injuries originating outside of the brain stem. Additionally, it has been implicated in the treatment of aphasia after hypoxic stroke. While the full mechanism is currently unknown, GABA stimulation appears to create paradoxical excitement in the brain, leading to a gradual recovery of cognitive, speech, and motor function. As of 2026, the usage of Zolpidem for this purpose is scattered but has gradually increased since the breakthrough study published in 2007.
15 June to 25 September Operation Iroquois Grove was a 1st Brigade, 5th Infantry Division (Mechanized) and 2nd Battalion, 5th Marines clear and search operation against PAVN Base Area 101 southeast of Quảng Trị City. the operation resulted in 134 PAVN and 13 U.S. killed.
== Clinicians == Physician Bachelor of Medicine, Bachelor of Surgery (MBBS) Doctor of Medicine (M.D.) Doctor of Osteopathic Medicine (D.O.) Dentist Bachelor of Dental Surgery (BDS) Doctor of Dental Medicine (DMD) Doctor of Dental Surgery (DDS) Optometrist Doctor of Optometry (OD) Podiatrist Doctor of Podiatry (DPM) Chiropractor Doctor of Chiropractic (DC) Physician Assistant (PA) Doctor of Medical Science (D.Med.Sc.), (D.M.Sc.) Master of Medical Science (M.Med.Sc), (M.M.Sc.) Master of Physician Assistant Studies (M.P.A.S.) Professional (Second-entry) Bachelor of Science in Physician Assistant (B.Sc.PA.), (B.H.Sc.PA) Pharmacist (R.Ph.) Doctor of Pharmacy (PharmD) Master of Pharmacy (MPharm) Bachelor of Pharmacy (B.Pharm)
== Safety == The safety characteristics of CDI have been investigated as part of a broader evaluation of amide bond forming reagents. CDI was demonstrated to exhibit dermal corrosion and eye irritation. The sensitization potential of CDI was shown to be low compared to other common amide bond forming agents (non-sensitizing at 1% in LLNA testing according to OECD 429). Thermal hazard analysis by differential scanning calorimetry (DSC) shows CDI poses minimal explosion risks.
Sources: en.wikipedia.org
The above cascade of (n,γ) reactions gives a mix of different curium isotopes. Their post-synthesis separation is cumbersome, so a selective synthesis is desired. Curium-248 is favored for research purposes due to its long half-life. The most efficient way to prepare this isotope is by α-decay of the californium isotope 252Cf, which is available in relatively large amounts due to its long half-life (2.65 years). About 35–50 mg of 248Cm is produced thus, per year. The associated reaction produces 248Cm with isotopic purity of 97%.
=== Avoiding bites === Rattlesnakes tend to avoid wide-open spaces where they cannot hide from predators, and generally avoid humans if they are aware of their approach. Rattlesnakes rarely bite unless they feel threatened or provoked. A majority of victims (about 72%) are males. Around half of bites occur in cases where the victim saw the snake, yet made no effort to move away. Harassing or attacking a rattlesnake, illegal in some jurisdictions, puts one at much higher risk of a bite. Rattlesnakes seek to avoid humans and other predators or large herbivores that themselves pose lethal danger. Dogs, often much more aggressive than humans, are much more likely to experience a snakebite, and are more likely to die of a rattlesnake bite although they can be vaccinated against them. Caution is advised even when snakes are believed to be dead; rattlesnake heads can sense, flick the tongue, and inflict venomous bites reflexively for up to an hour after being severed from the body.
=== C-terminal retention signals === While the N-terminus of a protein often contains targeting signals, the C-terminus can contain retention signals for protein sorting. The most common ER retention signal is the amino acid sequence -KDEL (Lys-Asp-Glu-Leu) or -HDEL (His-Asp-Glu-Leu) at the C-terminus. This keeps the protein in the endoplasmic reticulum and prevents it from entering the secretory pathway.
Sources: en.wikipedia.org
== History == Following World War II, Sonic founder Troy N. Smith Sr., returned to his hometown of Seminole, Oklahoma, where he became employed as a milkman. He then decided to work delivering bread, because bread is lighter than milk. Soon afterwards, Smith purchased the Cottage Cafe, a little diner in Shawnee, Oklahoma. Before long, he sold it and opened a fast-food service, Troy's Pan Full of Chicken, on the edge of town. In 1953, Smith joined with a business partner to purchase a five-acre parcel of land that had a log house and a walk-up root beer stand named the Top Hat. The two continued operating the root beer stand and converted the log house into a steak restaurant. After realizing that the stand was averaging $700 a week in the sale of root beer, hamburgers, and hot dogs, Smith decided to focus on the more-profitable root beer stand. He bought out his business partner. Initially, Top Hat customers parked their automobiles anywhere on the gravel parking lot and walked up to place orders. In Louisiana, Smith saw a drive-in that used speakers for ordering. He suspected that he could increase his sales by controlling the parking and having the customers order from speakers at their cars, with carhops delivering the food to the cars. Smith borrowed several automobiles from a friend who owned a used-car lot to establish a layout for controlled parking. He also had some so-called "jukebox boys" wire an intercom system in the parking lot. Sales immediately tripled. Charles Woodrow Pappe, an entrepreneur, was impressed by the Shawnee drive-in.
==== Inflammatory bowel disease (IBD)/cystitis ==== Despite strong preclinical rationale, efforts to demonstrate efficacy of SP antagonists in inflammatory disease have been unproductive. A study in women with IBS confirmed that an NK1RAs antagonist was anxiolytic.
This is a bibliography of works by Oscar Wilde (1854–1900), a late-Victorian Irish writer. Chiefly remembered today as a playwright, especially for The Importance of Being Earnest, and as the author of The Picture of Dorian Gray; Wilde's oeuvre includes criticism, poetry, children's fiction, and a large selection of reviews, lectures and journalism. His private correspondence has also been published. Wilde was declared bankrupt to pay legal costs after his conviction for "gross indecency," and his possessions – including manuscripts, letters, books and presentation volumes of all the major literary figures of his day – were sold by auction. This has made bibliographical (and biographical) studies of unpublished work more difficult since they are widely dispersed, some in private ownership. The largest collection of Wilde's letters, manuscripts, and other material relating to his literary circle are housed at the William Andrews Clark Memorial Library. A number of Wilde's letters and manuscripts can also be found at the British Library, as well as public and private collections throughout Britain, the United States and France.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.